盟科药业与海鲸药业签订战略合作协议

Core Insights - The strategic cooperation agreement between Mengke Pharmaceutical and Nanjing Haiqing Pharmaceutical aims to enhance market access and customer networks, focusing on deep commercialization partnerships in the antibacterial drug sales sector [1] - The sales revenue targets for the years 2026 to 2028 are set at 260 million, 388 million, and 600 million yuan respectively, contingent on successful market resource integration [1] - The partnership will leverage Nanjing Haiqing's expertise in raw material drug development to reduce product costs and improve profitability for Mengke Pharmaceutical [1] - Both companies are aligned with the "Healthy China 2030" strategy, aiming to establish an innovative product collaboration platform focusing on disease prevention and treatment [1] Summary by Sections Strategic Cooperation - Mengke Pharmaceutical and Nanjing Haiqing Pharmaceutical signed a strategic cooperation agreement on September 22, 2025, in Shanghai [1] - The collaboration will focus on market and customer network enhancement, utilizing existing commercial channels for effective promotion [1] Financial Projections - Sales revenue targets for Mengke Pharmaceutical are projected to reach 260 million yuan in 2026, 388 million yuan in 2027, and 600 million yuan in 2028 [1] Expertise and Cost Efficiency - Nanjing Haiqing specializes in raw material drug development, which will help Mengke Pharmaceutical lower product costs and enhance profitability [1] Innovation and Research - The partnership aims to create a product innovation collaboration platform, focusing on innovative research in treatment drugs and bioproducts, in line with national health strategies [1]